Is pomegranate good for weight loss?

Not in any way you would notice. A 2024 meta-analysis of 28 randomized trials, 1,124 adults in all, found pomegranate juice, extract or seed oil lowered body weight by 4.3 lb (1.97 kg) against control in the 22 trials that measured weight, which ran 2 to 24 weeks. One trial drives most of that. Without it the effect is 1.9 lb (0.86 kg), with an interval reaching down to 0.11 lb (0.05 kg), and under 2.2 lb (1 kg) over weeks to months is below what counts as clinically meaningful weight loss. Many participants already had type 2 diabetes, obesity, polycystic ovary syndrome, fatty liver disease or were on dialysis. No trial tested the whole fruit as a weight-loss food.

Myth. There is no sign that pomegranate reduces body fat. In the same 2024 meta-analysis, fat mass changed by 0.2 lb (0.09 kg) across 4 trials, with an interval from a 0.64 lb (0.29 kg) loss to a 0.24 lb (0.11 kg) gain, and waist circumference did not change in 11 trials. Weight that falls without fat falling may be water, gut content or chance.

What the trials found

One trial carries the result

When the authors of the 2024 meta-analysis removed the trials one at a time, dropping a single study, Stockton 2017, shrank the weight effect from 4.3 lb (1.97 kg) to 1.9 lb (0.86 kg). We did not obtain that trial, so we cannot tell you what it gave or to whom. The subgroups point the same way. Weight did not fall in trials shorter than 8 weeks, at extract doses under 1,000 mg a day, in people of normal weight or overweight, or with seed oil or extract as the product. What signal remains sits in people with obesity and metabolic disease, and those are comparisons across trials.

The largest pooling finds a very small effect

A 2025 meta-analysis of 53 randomized trials in 2,306 people found pomegranate products lowered body weight with a standardized difference of 0.14 and BMI with 0.17, and waist circumference and waist to hip ratio did not change. A standardized difference of 0.14 is a very small effect. The abstract prints those numbers with kilograms attached, which is a unit error, so the study gives a direction and cannot give a size in kilograms. Its list of outcomes that did not change is as long as its list of outcomes that did.

In diabetes and menopause, nothing

A 2020 meta-analysis of 7 randomized trials in 350 people with type 2 diabetes found pomegranate had no significant effect on metabolic markers, body weight and BMI included. Its abstract does not give the weight estimate. A 2024 review of studies in women around and after menopause found pomegranate raised HDL cholesterol and did not change BMI or weight. That review mixed randomized trials with uncontrolled studies and case reports, and it gives no pooled weight number.

Unsettled. The one positive number on this page, 4.3 lb (1.97 kg), depends on a single trial we could not read, in a pool of trials of juice, extracts and seed oil, many in people with metabolic disease. Strip that trial out and what is left is under a kilogram. That is why we cannot call the effect either real or absent with confidence, only too small to plan around.

Who should be careful

Not for everyone. If you take warfarin, keep your pomegranate intake steady and tell your clinician before you start or stop it. One case report describes a 64-year-old woman on warfarin whose INR fell below target after she stopped drinking pomegranate juice 2 to 3 times a week. It is one case with no rechallenge.

Capsules are a different product from the fruit. The NIH National Center for Complementary and Integrative Health says pomegranate juice is believed to be safe and the extract may also be safe, while root, stem and peel may be unsafe in large amounts. That matters here because several of the weight trials used peel or whole-fruit extracts in capsules. The same agency says pomegranate usually has no side effects, that some people get digestive symptoms, and that allergic reactions have been reported.

On other medicines, two studies in people found no interaction. In a crossover trial of 16 healthy adults, 6.8 fl oz (200 mL) of juice twice a day for 2 weeks left blood levels of midazolam, a test drug for the CYP3A enzyme, unchanged. A separate study found juice and extract left the CYP2C9 enzyme alone in people when tested with the drug flurbiprofen, though its abstract does not say how many took part. Each covers one enzyme and one drug. Across 15 randomized trials with 673 people, no adverse reactions were reported, and adverse events in those short trials were often not collected systematically.

Pregnancy has its own review, pomegranate and pregnancy. We hold no evidence on pomegranate in children.

What expert bodies say

The European Union has refused every health claim filed for pomegranate, eleven of them, covering cholesterol, prostate, sexual function, glucose, antioxidant effect and skin. None of the eleven was about weight. A refusal means the dossier did not convince the assessors, and the register does not give reasons. Europe has authorized no pomegranate claim of any kind, and the NIH pomegranate page says nothing about weight.

How we searched

What would change this answer

• A placebo-controlled trial of whole pomegranate or 100 percent juice, lasting 12 weeks or more, with weight as its main outcome, in people without metabolic disease. We found none in the literature or the trial registry.
• A look at the Stockton 2017 trial. If its result does not hold, the 2024 effect falls below a kilogram.
• Trials that measure fat directly. Only 4 trials in the 2024 analysis reported fat mass.

More on the fruit itself, from the juice to the capsule, is on the pomegranate page.

Sources

1. ev-pomwl-01 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of randomized controlled trials with GRADE · n = 1124
   Combined results from the random‐effects model indicated a significant reduction in body weight following the pomegranate intake (WMD: −1.97 kg 95% CI: −2.91 to −1.03; p ≤ .001; Figure 2a).
   
   Who: adults in RCTs of 2 to 24 weeks given pomegranate juice, extract or seed oil; many with type 2 diabetes, obesity, PCOS, NAFLD or on hemodialysis
   Effect: body weight WMD -4.3 lb (95% CI -6.4 to -2.3; metric: -1.97 kg, -2.91 to -1.03), I2 = 45.8%; 28 RCTs, 1124 participants overall
   Certainty: Fragile: leave-one-out shows one trial (Stockton 2017) drives the size; without it the effect is -1.9 lb (-0.86 kg). Authors' GRADE high looks generous given that.
   Food Science & Nutrition, 2024 · checked 2026-10-07 · we read the fulltext
2. ev-pomwl-02 · Meta-analysis or systematic review · sensitivity analysis within a meta-analysis of randomized controlled trials · n = —
   As a result, by removing the study Stockton et al. (2017) (WMD: −0.86, CI95%: −1.66, −0.05), results mentioned a significant alteration of the overall effect size.
   
   Who: RCTs pooled for body weight, leave-one-out sensitivity analysis
   Effect: without Stockton 2017: WMD -1.9 lb (95% CI -3.7 to -0.11; metric: -0.86 kg, -1.66 to -0.05)
   Certainty: Under 2.2 lb (1 kg) over weeks to months is below what counts as clinically meaningful weight loss.
   Food Science & Nutrition, 2024 · checked 2026-10-07 · we read the fulltext
3. ev-pomwl-03 · Meta-analysis or systematic review · subgroup analysis within a meta-analysis of randomized controlled trials · n = —
   The outcomes of subgroup analysis mentioned no significant decrease in body weight following the short‐term pomegranate intake (<8 weeks), low dose pomegranate extract intake (<1000 mg/day), or intervention among normal BMI or overweight participants.
   
   Who: RCT subgroups by duration, dose, baseline BMI and product type
   Effect: no significant weight loss: <8 weeks, extract <1000 mg/day, normal BMI or overweight, seed oil, extract as product type
   Certainty: Subgroups compare across trials; the remaining signal sits in obese participants with metabolic disease.
   Food Science & Nutrition, 2024 · checked 2026-10-07 · we read the fulltext
4. ev-pomwl-04 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of randomized controlled trials · n = —
   Combined results from the random‐effects model revealed that pomegranate consumption failed to reduce the fat mass significantly (WMD: −0.09 kg; 95% CI: −0.29 to 0.11; p = .374; Figure 2d).
   
   Who: adults in RCTs measuring body composition
   Effect: fat mass WMD -0.2 lb (95% CI -0.64 to 0.24; metric: -0.09 kg, -0.29 to 0.11); waist -0.27 in (95% CI -0.61 to 0.07; metric: -0.69 cm, -1.56 to 0.17); body fat % -0.64 (95% CI -1.33 to 0.04)
   Certainty: Few trials measured fat directly; weight without fat loss may be water, gut content or chance.
   Food Science & Nutrition, 2024 · checked 2026-10-07 · we read the fulltext
5. ev-pomwl-05 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials · n = 2306
   The findings revealed that PO supplementation substantially reduced body weight (standardized mean difference (SMD): -0.14 kg, 95 % CI: -0.25, -0.03; P = 0.01), diastolic blood pressure (DBP) (SMD: -0.39 mmHg, 95 % CI: -0.59, -0.18; P < 0.001), body mass index (BMI) (SMD: -0.17 kg/m2, 95 % CI: -0.30, -0.04; P = 0.01), systolic blood pressure (SBP) (SMD: -0.49 mmHg, 95 % CI: -0.68, -0.31; P < 0.001), serum fasting blood glucose (FBG) (SMD: -0.15 mg/dL, 95 % CI: -0.26, -0.04; P = 0.01), and total cholesterol (TC) (SMD: -0.12 mg/dL, 95 % CI: -0.24, -0.00; P = 0.04) while elevating high-density lipoprotein (HDL) levels (SMD: 0.27 mg/dL, 95 % CI: 0.08, 0.47; P < 0.001) compared to control groups.
   
   Who: participants of 53 RCTs of pomegranate products versus control, published to January 2024
   Effect: body weight SMD -0.14 (95% CI -0.25 to -0.03); BMI SMD -0.17 (-0.30 to -0.04); WC and WHR not changed
   Certainty: Reported as standardized mean differences (labeled kg in the abstract, which is a unit error); an SMD of 0.14 is a very small effect.
   Nutr Metab Cardiovasc Dis, 2025 · checked 2026-10-07 · we read the abstract
6. ev-pomwl-06 · Meta-analysis or systematic review · systematic review and random-effects meta-analysis of randomized controlled trials · n = 350
   The results of the meta-analysis revealed that pomegranate supplementation did not have any significant effects on metabolic status and oxidative stress biomarkers of subjects with T2DM.
   
   Who: adults with type 2 diabetes in RCTs of pomegranate supplementation
   Effect: no significant effect on BMI, body weight, glycemic markers, lipids, hs-CRP or TAC
   Certainty: Small trials; the abstract states no effect without giving the weight estimate.
   Complement Ther Med, 2020 · checked 2026-10-07 · we read the abstract
7. ev-pomwl-07 · Observational data · systematic review and meta-analysis including RCTs and uncontrolled clinical studies · n = —
   It significantly improves high-density lipoprotein but not low-density lipoprotein, body mass index, and weight.
   
   Who: peri- and postmenopausal women in RCTs, pre-post studies, case reports and case series
   Effect: HDL improved; LDL, BMI and weight not significantly changed; most results inconclusive
   Certainty: Mixed designs with high risk of bias, so graded below A.
   Phytother Res, 2024 · checked 2026-10-07 · we read the abstract
8. ev-pomwl-08 · Position of an expert body · government health information page · n = —
   Pomegranate root, stem, and peel may not be safe when consumed in large amounts because they contain substances that can have harmful effects.
   
   Who: adults using pomegranate juice, extract or other plant parts
   Effect: juice: believed safe; extract: may be safe; root, stem, peel: may not be safe in large amounts
   Certainty: Relevant because several weight trials used peel or whole-fruit extracts in capsules.
   NIH National Center for Complementary and Integrative Health, Pomegranate (Last Updated April 2025) · checked 2026-10-07 · we read the section
9. ev-pomwl-09 · Position of an expert body · government health information page · n = —
   Pomegranate usually doesn’t have side effects, but some people may have digestive tract symptoms.
   
   Who: people using pomegranate products
   Effect: digestive symptoms in some people; allergic reactions reported
   NIH National Center for Complementary and Integrative Health, Pomegranate (Last Updated April 2025) · checked 2026-10-07 · we read the section
10. ev-pomwl-10 · Laboratory or animal data · case report · n = 1
    She stopped drinking the juice, and her INRs became subtherapeutic.
    
    Who: one 64-year-old woman on warfarin 4 mg/day for recurrent deep vein thrombosis
    Effect: subtherapeutic INR after stopping juice; warfarin dose raised; Drug Interaction Probability Scale: possible
    Certainty: Single case, no rechallenge. People on warfarin who start or stop pomegranate should keep intake steady and tell their clinician.
    Pharmacotherapy, 2009 · checked 2026-10-07 · we read the abstract
11. ev-pomwl-11 · Randomized controlled trial(s) · open-label randomized 2-period crossover pharmacokinetic study (UMIN000004459) · n = 16
    Differences in the mean AUC(0-∞) were 12.7 (4.4) and 14.2 (6.6) ng/mL/h in pomegranate juice and control groups, respectively (geometric mean ratio: 1.02 [95% CI, 0.95-1.09]; P = 0.40).
    
    Who: healthy Japanese volunteers (11 men, 5 women), 6.8 fl oz (200 mL) juice twice daily for 2 weeks, single 15 ug/kg oral midazolam
    Effect: midazolam AUC geometric mean ratio 1.02 (95% CI 0.95 to 1.09); Cmax ratio 0.95 (0.79 to 1.11)
    Certainty: Healthy young adults and one probe drug; does not cover warfarin (CYP2C9) or every medicine.
    Clin Ther, 2011 · checked 2026-10-07 · we read the abstract
12. ev-pomwl-12 · Meta-analysis or systematic review · systematic review and meta-analysis of randomized controlled trials · n = 673
    No adverse reactions were reported in any of the studies.
    
    Who: healthy, overweight, obese, NAFLD, type 2 diabetes, PCOS, metabolic syndrome and hyperlipidemia participants in RCTs of at least 4 weeks
    Effect: no adverse reactions reported; no effect on HOMA-IR (WMD -0.03, 95% CI -0.37 to 0.31)
    Certainty: Absence of reported harm in short trials is not proof of safety; adverse events were often not systematically collected.
    Phytother Res, 2025 · checked 2026-10-07 · we read the abstract
13. pom-dr-03 · Meta-analysis or systematic review · systematic review and dose-response meta-analysis of randomized controlled trials of pomegranate supplementation on cardiovascular risk factors, searching PubMed, Scopus and Web of Science to January 2024, under a random-effects model with I squared for heterogeneity · n = 2306
    No substantial changes were observed in waist-to-hip ratio (WHR), homeostatic model assessment of insulin resistance (HOMA-IR), waist circumference (WC), serum values of hemoglobin A1c (HbA1c), alanine transaminase (ALT), triglycerides (TG), low-density lipoprotein (LDL), insulin, and aspartate transferase (AST) levels between PO and placebo groups.
    
    Who: participants in 53 randomized controlled trials
    Effect: standardized mean differences favored pomegranate for body weight, diastolic pressure, body mass index, systolic pressure, fasting glucose and total cholesterol, and for raising HDL; no substantial change appeared in waist-to-hip ratio, HOMA-IR, waist circumference, HbA1c, ALT, triglycerides, LDL, insulin or AST
    Certainty: the abstract prints standardized mean differences with units attached, for example SMD -0.49 mmHg, which is a mistake: a standardized mean difference has no units and cannot be read as millimeters. So this study tells you the direction across 53 trials and cannot tell you the size. Read next to the juice meta-analysis, which does give millimeters. The list of null outcomes is as long as the list of positive ones. Full text was not available to us
    Nutr Metab Cardiovasc Dis, 2025 · checked 2026-09-22 · we read the abstract
14. pom-dr-04 · Randomized controlled trial(s) · in vitro and in vivo evaluation of pomegranate juice and a 1 g pomegranate extract capsule as inhibitors of cytochrome P450 2C9, with flurbiprofen as the index substrate, fluconazole as a positive control inhibitor and a low-polyphenol beverage as the control · n = not given in the abstract
    Despite inhibition of CYP2C9 in vitro, pomegranate juice and extract had no effect on CYP2C9 activity in human subjects, and can be consumed by patients taking CYP2C9 substrate drugs with negligible risk of a pharmacokinetic interaction.
    
    Who: human volunteers, with parallel in vitro work
    Effect: in vitro half-maximal inhibitory concentrations for juice and extract were below 1% by volume with no mechanism-based inhibition, yet flurbiprofen pharmacokinetics were unchanged by either juice or extract against the control beverage, while fluconazole significantly reduced flurbiprofen clearance; the authors conclude pomegranate can be consumed by patients taking CYP2C9 substrate drugs with negligible risk
    Certainty: this tests one enzyme with one drug, so it does not clear pomegranate against every medication, and other enzymes such as CYP3A4 are not addressed here. The sample size is not given in the abstract. Its value is twofold: it answers a question people actually ask, and it is a clean example of a laboratory result that did not survive contact with human physiology, which is the usual fate of in vitro food-drug findings
    Clin Pharmacol Ther, 2012 · checked 2026-09-22 · we read the abstract
15. pom-dr-07 · Position of an expert body · EU Register on nutrition and health claims, claim POL-HC-7792, snapshot of 2026-09-21 · n = —
    POL-HC-7792 Pomegranate Helps to maintain a healthy prostate. Contributes to healthy sexual function in men. Non-authorised
    
    Who: —
    Effect: the entry claiming that pomegranate helps maintain a healthy prostate and contributes to healthy sexual function in men carries the status Non-authorized; across the eleven register entries naming pomegranate, pomegranate juice, its extracts or Punica granatum in this snapshot, authorized claims number zero and refusals eleven, covering cholesterol, prostate, sexual function, glucose, antioxidant effect and skin
    Certainty: eleven refusals mean eleven dossiers did not convince the assessors, not that pomegranate does nothing: the register carries no reasons, which live in EFSA opinions we do not hold. The comparison worth drawing is with the trial evidence on this page, which does find small effects on blood pressure. A regulator refusing a claim and a meta-analysis finding an effect are answering different questions with different burdens of proof
    EU Register on nutrition and health claims, claim POL-HC-7792, snapshot of 2026-09-21 · checked 2026-09-22 · we read the row